CCL2 and myeloid sarcoma: In one study, plasma soluble CD40L (sCD40L) resulted significantly increased in SPMS patients compared to non-progressive benign MS, and the combination of plasma sCD40L with monocyte chemoattractant protein 1 (MCP1) showed great accuracy in differentiating RRMS and SPMS patients [53].